Independent register of U.S. FDA drug recalls · updated Oct 10, 2026
RxRecalls Get alerts
Class III · Low risk Ongoing Initiated Jun 1, 2026 (4 months ago)

Fexofenadine Hydrochloride Tablets

Class III — Low risk. Unlikely to cause harm, but violates FDA regulations.

Why it was recalled

Failed Impurities/Degradation Specifications

Cause type: Impurity / degradation

An impurity or degradation product above its limit - other than nitrosamines. Unexpected substances in a batch can make it unsafe or less effective, even when the active ingredient is present. All impurity / degradation recalls.

What was recalled

Fexofenadine Hydrochloride Tablets, USP 180 mg, Antihistamine, 150 Tablets per bottle, Distributed by: Ohm Laboratories, Inc., New Brunswick, NJ 08901. NDC 66336-561-30

Affected NDC 66336-0561-30

Compare with the code on your package — it is the most precise check available.

Drug: Fexofenadine Category: Allergy & Cold Medication

Recalling firm
Sun Pharmaceutical Industries INC
NDC code
66336-561-30
Origin
NJ, United States
Initiated by
Voluntary: Firm initiated
FDA recall number
D-0654-2026 · FDA notice

Low risk, still worth a check. Class III means the product is unlikely to cause harm but breaks an FDA rule (often labeling). If your lot matches, your pharmacy will normally swap it; there is no need for alarm.

Other Fexofenadine recalls

See all
Class II · Moderate risk

Fexofenadine Hydrochloride Tablets

CGMP Deviations: Microbial contamination was reported in stagnant water in the duct of the manufacturing equipment.

Completed Microbial contamination Sun Pharmaceutical Industries INC NDC 51660-998-30 D-0273-2024
Class II · Moderate risk

Allergy Relief

Failed Impurities/Degradation Specifications

Terminated Impurity / degradation L. Perrigo Company NDC 36800-691-39 D-0912-2023
Class II · Moderate risk

Picnic

Failed Impurities/Degradation Specifications

Terminated Impurity / degradation L. Perrigo Company D-0911-2023
Class II · Moderate risk

allergy relief

Failed Impurities/Degradation Specifications

Terminated Impurity / degradation L. Perrigo Company NDC 11673-617-22 D-0910-2023
Class II · Moderate risk

allergyrelief

Failed Impurities/Degradation Specifications

Terminated Impurity / degradation L. Perrigo Company NDC 56062-847-39 D-0909-2023

Other recalls by Sun Pharmaceutical Industries INC

All 2026 recalls
Class II · Moderate risk

Carbamazepine Tablets

CGMP Deviations; black spots found on tablets from burnt excipient during manufacturing

Ongoing cGMP deviation Sun Pharmaceutical Industries INC NDC 51672-4005-3 D-0770-2026
Class II · Moderate risk

Perampanel CIII Tablets

Labeling: Label Mix-up: 10mg Perampanel CIII tablet was found in a Perampanel CIII bottle labeled Perampanel 6 mg tablets.

Ongoing Labeling / mix-up Sun Pharmaceutical Industries INC NDC 51672-4206-6 D-0628-2026
Class II · Moderate risk

Budesonide Inhalation Suspension

Presence of Foreign Substance:This recall has been initiated in response to a product quality complaint reported for black/brown specs and particles within the ampoule solution

Ongoing Particulate / foreign matter Sun Pharmaceutical Industries INC NDC 47335-633-49 D-0607-2026